HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline

/PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of...

Related Keywords

United States ,Robert Stoffel ,Ryan Feaver ,Prnewswire Hemoshear Therapeutics Inc ,Nasdaq ,Fifth Milestone Achieved ,Novel Compounds ,Shear Therapeutics ,Horizon Therapeutics ,Hemoshear Therapeutics ,